U.S. COVID-19 Vaccine Product Information

Janssen COVID-19 Vaccine (Johnson & Johnson): Effective April 23, 2021, CDC and FDA recommend that use of the Janssen COVID-19 Vaccine resume in the United States. However, women younger than 50 years old should be made aware of a rare risk of blood clots with low platelets following vaccination and the availability of other COVID-19 vaccines where this risk has not been observed. Read the CDC/FDA statement.

CDC will publish an update in Morbidity and Mortality Weekly Report early next week related to the Advisory Committee on Immunization Practices (ACIP) recommendation and is updating relevant clinical materials and guidance.

Find a suite of information and materials that are needed for each specific COVID-19 vaccine that cover administration, storage and handling, safety, and reporting.

Page last reviewed: March 2, 2021